External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia

Stefano Molica, Diana Giannarelli, Massimo Gentile, Giovanna Cutrona, Nicola Di Renzo, Francesco Di Raimondo, Antonino Neri, Massimo Federico, Manlio Ferrrarini, Fortunato Morabito

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: A nomogram that incorporates traditional and newer prognostic factors to identify patients with chronic lymphocytic leukemia (CLL) who are at high risk of receiving therapy was developed by investigators at The University of Texas M. D. Anderson Cancer Center (MDACC). Because the model required validation before its extensive use could be recommended, the authors sought to externally validate the nomogram in an independent, community-based cohort of patients with CLL. METHODS: In total, 328 previously untreated patients with newly diagnosed, asymptomatic, Binet stage A CLL from different primary hematology centers who were registered on a prospective basis during 2006 to 2010 on an observational database of the Italian Lymphoma Study Group were considered suitable for external validation of the model. RESULTS: A total point score was calculated for each patient using a formula proposed by MDACC investigators, and the median score was 19.9 (range, 0-69.5). Furthermore, when the score was evaluated as continuous variable (ie, by measuring the risk of each point increase), the total point score was associated with the time to first treatment (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.02-1.05; P 2] = 0.966; P =.002). CONCLUSIONS: The current results confirmed the ability of a newly developed prognostic index to predict the time to first treatment among previously untreated patients with CLL who had early disease and extended the utility of the model to those with Rai stage 0 disease. In addition, the actual and predicted time to first treatment outcomes revealed good agreement, suggesting that, externally, the results provided by the model are well calibrated. Cancer 2013.

Original languageEnglish
Pages (from-to)1177-1185
Number of pages9
JournalCancer
Volume119
Issue number6
DOIs
Publication statusPublished - Mar 15 2013

Fingerprint

Nomograms
B-Cell Chronic Lymphocytic Leukemia
Research Personnel
Therapeutics
Neoplasms
Hematology
Lymphoma
Databases
Confidence Intervals

Keywords

  • early chronic lymphocytic leukemia
  • nomogram validation
  • prognostic index
  • time to first treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. / Molica, Stefano; Giannarelli, Diana; Gentile, Massimo; Cutrona, Giovanna; Di Renzo, Nicola; Di Raimondo, Francesco; Neri, Antonino; Federico, Massimo; Ferrrarini, Manlio; Morabito, Fortunato.

In: Cancer, Vol. 119, No. 6, 15.03.2013, p. 1177-1185.

Research output: Contribution to journalArticle

Molica, Stefano ; Giannarelli, Diana ; Gentile, Massimo ; Cutrona, Giovanna ; Di Renzo, Nicola ; Di Raimondo, Francesco ; Neri, Antonino ; Federico, Massimo ; Ferrrarini, Manlio ; Morabito, Fortunato. / External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. In: Cancer. 2013 ; Vol. 119, No. 6. pp. 1177-1185.
@article{30f390d2b77b4784bf14019d067440bc,
title = "External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia",
abstract = "Background: A nomogram that incorporates traditional and newer prognostic factors to identify patients with chronic lymphocytic leukemia (CLL) who are at high risk of receiving therapy was developed by investigators at The University of Texas M. D. Anderson Cancer Center (MDACC). Because the model required validation before its extensive use could be recommended, the authors sought to externally validate the nomogram in an independent, community-based cohort of patients with CLL. METHODS: In total, 328 previously untreated patients with newly diagnosed, asymptomatic, Binet stage A CLL from different primary hematology centers who were registered on a prospective basis during 2006 to 2010 on an observational database of the Italian Lymphoma Study Group were considered suitable for external validation of the model. RESULTS: A total point score was calculated for each patient using a formula proposed by MDACC investigators, and the median score was 19.9 (range, 0-69.5). Furthermore, when the score was evaluated as continuous variable (ie, by measuring the risk of each point increase), the total point score was associated with the time to first treatment (hazard ratio [HR], 1.04; 95{\%} confidence interval [CI], 1.02-1.05; P 2] = 0.966; P =.002). CONCLUSIONS: The current results confirmed the ability of a newly developed prognostic index to predict the time to first treatment among previously untreated patients with CLL who had early disease and extended the utility of the model to those with Rai stage 0 disease. In addition, the actual and predicted time to first treatment outcomes revealed good agreement, suggesting that, externally, the results provided by the model are well calibrated. Cancer 2013.",
keywords = "early chronic lymphocytic leukemia, nomogram validation, prognostic index, time to first treatment",
author = "Stefano Molica and Diana Giannarelli and Massimo Gentile and Giovanna Cutrona and {Di Renzo}, Nicola and {Di Raimondo}, Francesco and Antonino Neri and Massimo Federico and Manlio Ferrrarini and Fortunato Morabito",
year = "2013",
month = "3",
day = "15",
doi = "10.1002/cncr.27900",
language = "English",
volume = "119",
pages = "1177--1185",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia

AU - Molica, Stefano

AU - Giannarelli, Diana

AU - Gentile, Massimo

AU - Cutrona, Giovanna

AU - Di Renzo, Nicola

AU - Di Raimondo, Francesco

AU - Neri, Antonino

AU - Federico, Massimo

AU - Ferrrarini, Manlio

AU - Morabito, Fortunato

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Background: A nomogram that incorporates traditional and newer prognostic factors to identify patients with chronic lymphocytic leukemia (CLL) who are at high risk of receiving therapy was developed by investigators at The University of Texas M. D. Anderson Cancer Center (MDACC). Because the model required validation before its extensive use could be recommended, the authors sought to externally validate the nomogram in an independent, community-based cohort of patients with CLL. METHODS: In total, 328 previously untreated patients with newly diagnosed, asymptomatic, Binet stage A CLL from different primary hematology centers who were registered on a prospective basis during 2006 to 2010 on an observational database of the Italian Lymphoma Study Group were considered suitable for external validation of the model. RESULTS: A total point score was calculated for each patient using a formula proposed by MDACC investigators, and the median score was 19.9 (range, 0-69.5). Furthermore, when the score was evaluated as continuous variable (ie, by measuring the risk of each point increase), the total point score was associated with the time to first treatment (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.02-1.05; P 2] = 0.966; P =.002). CONCLUSIONS: The current results confirmed the ability of a newly developed prognostic index to predict the time to first treatment among previously untreated patients with CLL who had early disease and extended the utility of the model to those with Rai stage 0 disease. In addition, the actual and predicted time to first treatment outcomes revealed good agreement, suggesting that, externally, the results provided by the model are well calibrated. Cancer 2013.

AB - Background: A nomogram that incorporates traditional and newer prognostic factors to identify patients with chronic lymphocytic leukemia (CLL) who are at high risk of receiving therapy was developed by investigators at The University of Texas M. D. Anderson Cancer Center (MDACC). Because the model required validation before its extensive use could be recommended, the authors sought to externally validate the nomogram in an independent, community-based cohort of patients with CLL. METHODS: In total, 328 previously untreated patients with newly diagnosed, asymptomatic, Binet stage A CLL from different primary hematology centers who were registered on a prospective basis during 2006 to 2010 on an observational database of the Italian Lymphoma Study Group were considered suitable for external validation of the model. RESULTS: A total point score was calculated for each patient using a formula proposed by MDACC investigators, and the median score was 19.9 (range, 0-69.5). Furthermore, when the score was evaluated as continuous variable (ie, by measuring the risk of each point increase), the total point score was associated with the time to first treatment (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.02-1.05; P 2] = 0.966; P =.002). CONCLUSIONS: The current results confirmed the ability of a newly developed prognostic index to predict the time to first treatment among previously untreated patients with CLL who had early disease and extended the utility of the model to those with Rai stage 0 disease. In addition, the actual and predicted time to first treatment outcomes revealed good agreement, suggesting that, externally, the results provided by the model are well calibrated. Cancer 2013.

KW - early chronic lymphocytic leukemia

KW - nomogram validation

KW - prognostic index

KW - time to first treatment

UR - http://www.scopus.com/inward/record.url?scp=84874675941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874675941&partnerID=8YFLogxK

U2 - 10.1002/cncr.27900

DO - 10.1002/cncr.27900

M3 - Article

C2 - 23224939

AN - SCOPUS:84874675941

VL - 119

SP - 1177

EP - 1185

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -